Article
Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
Journal of viral hepatitis - 1 Dec 2016
Willemse S B, Baak L C, Kuiken S D, van der Sluys Veer A, Lettinga K D, van der Meer J T M, Depla A C T M, Tuynman H, van Nieuwkerk C M J, Schinkel C J, Kwa D, Reesink H W, van der Valk M
Abstract excerpt
Chronic hepatitis C virus (HCV) infection is a major cause of chronic liver disease and liver-related death. Recently, multiple regimens of different direct-acting antiviral agents (DAAs) have been registered. Although treatment with sofosbuvir (SOF) and simeprevir (SMV) is registered for the treatment of genotype 4 patients in some countries, data on efficacy of this combination are lacking. We aimed to assess...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.